Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Pleased to share our paper.”
Title: Beyond one gene, one target: Next-generation precision oncology
Authors: Vivek Subbiah and Razelle Kurzrock
Read the full article.
To which Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, added:
One gene/one target has a ceiling in complex cancers. Either treat earlier before complex evolution or give biomarker matched combinations or both.
Pleasure to work with Vivek Subbiah on this concept.
Other articles featuring Razelle Kurzrock and Vivek Subbiah on OncoDaily.